Calcium Dobesilate After Radiofrequency Ablation for Varicose Veins

Starting soon · Phase 4

Conditions studied: Varicose Veins Leg, Great Saphenous Vein Insufficiency, Chronic Venous Insufficiency

In brief

This study evaluates whether calcium dobesilate, a venoactive drug, improves recovery after radiofrequency ablation (RFA) for varicose veins. Patients with great saphenous vein insufficiency undergoing RFA will be randomly assigned to receive either calcium dobesilate (500 mg twice daily) or standard care alone. The treatment starts 7 days before the procedure and continues for 30 days after. The primary outcome is postoperative pain at day 7. Secondary outcomes include pain at days 14 and 30, quality of life, ecchymosis, and return to daily activities.

Key facts

Study ID

NCT07390097

Run by

Oguz Arslanturk

People needed

250

Starts

2026-02-28

Expected to finish

2026-11-01

Last updated by the study team

2026-02-05

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-70 years
• Symptomatic primary varicose veins (CEAP classification C2-C4)
• Great saphenous vein insufficiency confirmed by duplex ultrasound (reflux >0.5 seconds)
• Great saphenous vein diameter 5-12 mm
• Scheduled for radiofrequency ablation
• Able to provide written informed consent

You may not qualify if…

• History of deep vein thrombosis
• Peripheral arterial disease (ABI <0.9)
• Active venous ulcer (CEAP C6)
• Pregnancy or breastfeeding
• Severe renal or hepatic insufficiency
• Known allergy to calcium dobesilate
• Use of venoactive drugs within the past 4 weeks
• Current anticoagulant therapy
• Previous venous intervention on the same limb
• Bilateral disease requiring simultaneous treatment
• Inability to comply with follow-up schedule

Where it is running

• Zonguldak Bulent Ecevit University Hospital, Department of Cardiovascular Surgery — Kozlu, Zonguldak Province, Turkey (Türkiye)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.